Home Newsfeeds Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

Goldman Sachs Maintains Neutral on Dun & Bradstreet Hldgs, Lowers Price Target to $15

By Benzinga Newsdesk

November 7, 9:06 AM

Goldman Sachs analyst George Tong maintains Dun & Bradstreet Hldgs (NYSE:DNB) with a Neutral and lowers the price target from $17 to $15.

DNB

EXCLUSIVE: Why Rep. David Joyce Says ‘Education Is The Key’ To Cannabis Reform

By Nina Zdinjak

September 13, 3:15 PM

What does the future hold for the cannabis industry in legislative terms?

CRLBF

Analyst Ratings

Analyst Ratings for L3Harris Technologies

By Benzinga Insights

Today, 3:27 PM

Over the past 3 months, 4 analysts have published their opinion on L3Harris Technologies (NYSE:LHX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

LHX

Kopin Receives Initial Production Order For Advanced Surgical Information Display; No Financial Terms Disclosed

By Benzinga Newsdesk

January 23, 9:31 AM

Kopin Corporation (NASDAQ:KOPN), a leading provider of application-specific optical solutions and high performance micro-displays for defense, enterprise, consumer and medical products, today announced it has received an

KOPN

Oppenheimer Downgrades Relmada Therapeutics to Perform

Related Posts

Goldman Sachs Maintains Neutral on Dun & Bradstreet Hldgs, Lowers Price Target to $15

EXCLUSIVE: Why Rep. David Joyce Says ‘Education Is The Key’ To Cannabis Reform

Analyst Ratings for L3Harris Technologies

Kopin Receives Initial Production Order For Advanced Surgical Information Display; No Financial Terms Disclosed